表紙
市場調査レポート

EpiCast Report:特発性肺線維症(IPF)の疫学的予測

EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025

発行 GlobalData 商品コード 268835
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
EpiCast Report:特発性肺線維症(IPF)の疫学的予測 EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2025
出版日: 2016年06月07日 ページ情報: 英文 55 Pages
概要

世界主要6ヶ国における特発性肺線維症(IPF)の発症件数は、2012〜2022年に年平均(CAGR)2.01%で増加して、2022年には45,718件に達すると予想されています。

当レポートでは、世界の主要6ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国)における特発性肺線維症(以下IPF)の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の罹患・普及状況、今後10年間の発症件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概況
  • 関連調査

第3章 疫学

  • 疾患の背景事情
  • リスク要因と共存症
    • 長期的な喫煙者の間では、IPFのリスクは見られない
    • 一般的職場での吸入は、様々な職業の人々に大きなリスクをもたらす
    • 胃食道逆流(GER)は、IPF患者に広く見られる疾患である
  • 世界各国の動向
    • 米国
    • EU主要5ヶ国
  • 予測手法
    • 利用した情報源
    • 予測の仮定・手法
    • 利用しなかった情報源
  • IPFの疫学的予測:今後10年間分
    • 発症率(全体)
    • 発症率(年齢層別)
    • 発症率(男女別)
    • 有病率(全体)
    • 有病率(年齢層別)
    • 有病率(男女別)
  • 議論
    • 疫学的傾向に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER121-16

The American Thoracic Society (ATS) defines IPF as a chronic, fibrosing interstitial pneumonia of unknown cause, which occurs primarily in older adults. IPF is characterized by variable degrees of inflammation and scarring and is associated with a histologic or radiologic pattern of usual interstitial pneumonia (UIP). IPF is the most common form of idiopathic interstitial pneumonia, having the worst prognosis, and only three to five years of median survival. IPF is more common in men and the incidence and prevalence of IPF typically increases with advancing age.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed incident cases of IPF will increase from 53,139 cases in 2015 to 62,258 cases in 2025, at an Annual Growth Rate (AGR) of 1.72%. The US will have the highest number of diagnosed incident cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest. The diagnosed prevalent cases of IPF will also increase from 118,943 cases in 2015 to 137,984 cases in 2025, at an AGR of 1.60%. The US will have the highest number of diagnosed prevalent cases of IPF among the 7MM throughout the forecast period, while Spain will have the lowest.

For this analysis, GlobalData epidemiologists used data from large comprehensive healthcare databases and country-specific studies published in peer-reviewed journals to estimate the diagnosed incident and diagnosed prevalent cases of IPF in addition to sources that provided data for cases confirmed through both biopsy of the lung and HRCT. Diagnosed incident and diagnosed prevalent cases were further segmented by age and sex to provide more detailed characteristics regarding the diseased population. The use of studies with consistent methodology across the 7MM provides a significant measure to compare the underlying burden of IPF across the 7MM. Additionally, GlobalData epidemiologists provided the diagnosed incident and diagnosed prevalent cases of IPF in the 7MM, except Japan, segmented by severity (mild, moderate, and severe) based on GAP index, which can be of importance for predicting the prognosis and course of treatment.

Scope

  • The Idiopathic Pulmonary Fibrosis (IPF) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for IPF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident and diagnosed prevalent cases of IPF segmented by sex, age (in five-year increments beginning at 18 years and ending at =85 years), and severity in these markets.
  • The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The IPF EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global IPF market.
  • Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for IPF therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Epidemiology

  • 2.1. Risk Factors and Comorbidities
  • 2.2. Global Trends
    • 2.2.1. Incidence
    • 2.2.2. Prevalence
  • 2.3. Forecast Methodology
    • 2.3.1. Sources Used
    • 2.3.2. Forecast Assumptions and Methods
    • 2.3.3. Sources Not Used
  • 2.4. Epidemiological Forecast for IPF (2015-2025)
    • 2.4.1. Diagnosed Incident Cases
    • 2.4.2. Diagnosed Prevalent Cases
    • 2.4.3. IPF Mortality
  • 2.5. Discussion
    • 2.5.1. Epidemiological Forecast Insight
    • 2.5.2. Limitations of the Analysis
    • 2.5.3. Strengths of the Analysis

3. Appendix

  • 3.1. Bibliography
  • 3.2. About the Authors
    • 3.2.1. Epidemiologist
    • 3.2.2. Reviewers
    • 3.2.3. Global Director of Therapy Analysis and Epidemiology
    • 3.2.4. Global Head of Healthcare
  • 3.3. About GlobalData
  • 3.4. About EpiCast
  • 3.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities of IPF
  • Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of IPF
  • Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF
  • Table 4: 7MM, except Japan, Sources Used to Forecast Severity Segmentation of Diagnosed Incident Cases and Diagnosed Prevalent Cases of IPF
  • Table 5: 7MM, Sources Used to Forecast IPF Deaths
  • Table 6: 7MM, Sources Not Used in the Epidemiological Analysis of IPF
  • Table 7: 7MM, Diagnosed Incident Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 8: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N (Row %), 2015
  • Table 9: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages ≥18 Years, N (Row %), 2015
  • Table 10: 7MM, Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 11: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N (Row %), 2015
  • Table 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, N (Row %), 2015
  • Table 13: 7MM, IPF Deaths, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Table 14: 7MM, Age-Specific IPF Deaths, Both Sexes, N (Row %), 2015
  • Table 15: 7MM, Sex-Specific IPF Deaths, Ages ≥18 Years, N (Row %), 2015

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of IPF, Ages ≥18 Years, Both Sexes, N, 2015-2025
  • Figure 2: 7MM, Age-Specific Diagnosed Incident Cases of IPF, Both Sexes, N, 2015
  • Figure 3: 7MM, Sex-Specific Diagnosed Incident Cases of IPF, Ages ≥18 Years, 2015
  • Figure 4: 7MM, Age-Standardized Diagnosed Incidence of IPF, Ages ≥18 Years, N, 2015
  • Figure 5: US and 5EU, Diagnosed Incident Cases of IPF by Severity, Both Sexes, Ages ≥18, 2015
  • Figure 6: 7MM, Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of IPF, Both Sexes, N, 2015
  • Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of IPF, Ages ≥18 Years, 2015
  • Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of IPF, Ages ≥18 Years, N, 2015
  • Figure 10: US and 5EU, Diagnosed Prevalent Cases of IPF by Severity, Both Sexes, Ages ≥18 Years, 2015
  • Figure 11: 7MM, IPF Deaths, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025
  • Figure 12: 7MM, Age-Specific IPF Deaths, Both Sexes, N, 2015
  • Figure 13: 7MM, Sex-Specific IPF Deaths, Ages ≥18 Years, 2015
Back to Top